Analysts Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Target Price at $46.90

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $46.90.

A number of analysts have recently weighed in on the stock. Guggenheim assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, April 14th. They issued a “buy” rating and a $54.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. JonesTrading started coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Tyra Biosciences in a report on Thursday, May 14th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a research report on Wednesday.

Tyra Biosciences News Roundup

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $45 price target for Tyra Biosciences, implying substantial upside from the stock’s recent trading level. The firm’s continued bullish stance provides some support despite weaker earnings forecasts.
• Neutral Sentiment: Analysts expect Tyra to remain unprofitable, forecasting losses of approximately $2.86 per share in fiscal 2026 and $3.20 per share in fiscal 2027. These estimates highlight the company’s ongoing investment needs as it advances its biotechnology pipeline.
• Negative Sentiment: HC Wainwright reduced its EPS estimates across the forecast period, including fiscal 2026 from ($2.74) to ($2.86) and fiscal 2027 from ($3.09) to ($3.20). Quarterly estimates for Q3 and Q4 2026 and each quarter of 2027 were also lowered, signaling expectations for greater near-term cash burn and losses.
• Negative Sentiment: Tyra previously reported a quarterly loss of ($0.69) per share, wider than analysts’ consensus estimate of ($0.65). The earnings shortfall triggered a gap lower in the shares and appears to be the main immediate pressure on the stock. Tyra Biosciences Shares Gap Down on Disappointing Earnings
• Neutral Sentiment: Analysts currently have a consensus recommendation of “Moderate Buy”, suggesting that Wall Street remains generally constructive on Tyra’s longer-term prospects, although near-term earnings revisions are weighing on sentiment. Tyra Biosciences Given Consensus Recommendation of Moderate Buy

Institutional Trading of Tyra Biosciences

Several hedge funds have recently added to or reduced their stakes in TYRA. BlackRock Inc. bought a new position in Tyra Biosciences in the 2nd quarter worth approximately $96,841,000. Deutsche Bank AG bought a new stake in Tyra Biosciences in the 2nd quarter valued at $1,180,000. Bank of New York Mellon Corp bought a new stake in Tyra Biosciences in the 2nd quarter valued at $3,313,000. State of Wyoming acquired a new stake in Tyra Biosciences in the 2nd quarter worth $76,000. Finally, Walleye Capital LLC acquired a new stake in Tyra Biosciences in the 2nd quarter worth $11,112,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $26.51 on Thursday. The stock’s 50 day simple moving average is $30.05 and its 200 day simple moving average is $32.66. Tyra Biosciences has a twelve month low of $9.96 and a twelve month high of $40.65. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -11.05 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, analysts forecast that Tyra Biosciences will post -2.72 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.